Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003802 · ClinicalTrials.gov registry record · Phase 2
Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma
A Phase 2 study of Melanoma (Skin) and Intraocular Melanoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00003802 is a Phase 2 study of Melanoma (Skin) and Intraocular Melanoma that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The trial reports 1 study location across 1 state.
The verdict
NCT00003802, a Phase 2 study of Melanoma (Skin) and Intraocular Melanoma, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have metastatic skin or eye melanoma.
Conditions Studied
Interventions
- DRUG pyrazoloacridine
Study Locations (1)
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-02 |
| Est. Completion | 2002-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003802
The ClinicalTrials.gov registry entry for NCT00003802 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma (Skin) appearing as the primary indexed condition, and to 1 intervention - of which pyrazoloacridine is the first listed.
NCT00003802 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00003802 about?
NCT00003802 is a clinical study titled "Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of pyrazoloacridine in treating patients who have metastatic skin or eye melanoma.
What is the current status of trial NCT00003802?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-02. Estimated completion is 2002-10.
What conditions does trial NCT00003802 study?
This clinical trial studies the following conditions: Melanoma (Skin), Intraocular Melanoma.
What interventions are being tested in trial NCT00003802?
The interventions under investigation include: pyrazoloacridine (DRUG).
Who is sponsoring clinical trial NCT00003802?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003802 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma (Skin)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
RECRUITING · Phase 2
-
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
RECRUITING · Phase 2
-
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma
COMPLETED · Phase 2
-
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 2
-
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.